Belotecan

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Belotecan
Belotecan.svg
Clinical data
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C25H27N3O4
Molar mass 433.50 g/mol
3D model (Jmol)
  (verify)

Belotecan is a drug used in chemotherapy. It is a semi-synthetic camptothecin analogue indicated for Small Cell Lung Cancer and Ovarian Cancer, approved in South Korea under the trade name Camtobell(R), presented in 2 mg vials for injection.[1] The drug is marketed by ChongKunDang Pharmaceuticals [2] since 2003 [3]

Belotecan blocks topoisomerase I with a pIC50 of 6.56,[4] stabilizing the cleavable complex of topoisomerase I-DNA, which inhibits the religation of single-stranded DNA breaks generated by topoisomerase I; lethal double-stranded DNA breaks occur when the topoisomerase I-DNA complex is encountered by the DNA replication machinery, DNA replication is disrupted, and the tumor cell undergoes apoptosis. Topoisomerase I is an enzyme that mediates reversible single-strand breaks in DNA during DNA replication.

References[edit]

  1. ^ http://www.ckdpharm.com/eng/ckd/product/productView.ckd?seq=2463
  2. ^ http://www.ckdpharm.com/eng/ckd/index.ckd
  3. ^ Sahoo, Umakanta (2012). Clinical Research in Asia: Opportunities and Challenges. Oxford: Woodhead Publishing Limited. p. 152. ISBN 978-1-908818-13-3. New drugs approved in South Korea 
  4. ^ "belotecan". drugcentral.org. UNM School of Medicine. 2016-07-31. Retrieved 2016-11-12.